517 completed, 103 recruiting, 51 active not recruiting, 40 not yet recruiting. 796 Phase 1, 153 Phase 2.
Follow Overweight: new trials by email Literature Review of Overweight trials Research Report on Overweight
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Human Models of Selective Insulin Resistance: Pancreatic Clamp Insulin human, Octreotide Acetate, Glucagon - Insulin Resistance, Hyperinsulinemia | Phase 1 | Not yet recruiting | Columbia University | 36 | 2027-01-01 | 2026-02-06 |
| Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients Metformin, Val, Cel and Met XR Low, Val, Cel and Met XR High - Type 2 Diabetes, High Blood Pressure | Phase 1 / Phase 2 | Withdrawn | ARKAY Therapeutics | 2026-12-10 | 2026-07-16 | |
| A Study to Evaluate a Single Dose of IBIO-610 in Participant With Obesity. IBIO-610, Placebo - Obesity & Overweight | Phase 1 | Not yet recruiting | iBio, Inc. | 32 | 2026-12-01 | 2026-10-22 |
| Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy Semaglutide (Rybelsus®), Placebo - Duchenne Muscular Dystrophy (DMD) | Phase 1 / Phase 2 | Recruiting | Vanderbilt University Medical Center | 30 | 2026-12-01 | 2026-11-12 |
| Investigating the Effects of 24 Hour LEAP2 Infusion in Individuals With Overweight and Obesity Liver-expressed antimicrobial peptide 2, Placebo - Obesity & Overweight | Phase 1 / Phase 2 | Not yet recruiting | University Hospital, Gentofte, Copenhagen | 18 | 2026-11-30 | 2026-10-27 |
| A Phase I Clinical Trial of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of UBT48128 Tablets in Healthy Participants UBT48128, Placebo - Overweight , Obesity | Phase 1 | Not yet recruiting | The United Bio-Technology (Hengqin) Co., Ltd. | 60 | 2026-11-29 | 2026-11-06 |
| A Study of Zovaglutide (ZT002 Injection) in Participants With Hepatic Impairment and Healthy Participants Zovaglutide - Overweight, Obesity | Phase 1 | Not yet recruiting | Beijing QL Biopharmaceutical Co.,Ltd | 24 | 2026-11-13 | 2026-11-04 |
| Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) Maridebart cafraglutide - Obesity, Overweight | Phase 1 | Recruiting | Amgen | 180 | 2026-11-13 | 2026-11-02 |
| Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations After Multiple Doses Maridebart cafraglutide - Obesity, Overweight | Phase 1 | Not yet recruiting | Amgen | 356 | 2026-11-09 | 2026-11-06 |
| A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234 AZD9550 solution for injection, AZD6234 solution for injection, Formulation 1 solution for injection - Healthy Participants | Phase 1 | Not yet recruiting | AstraZeneca | 60 | 2026-11-09 | 2026-11-02 |
| A Study of LY4247147 in Participants With Obesity or Overweight Who Are Otherwise Healthy LY4247147, Placebo - Obesity, Overweight | Phase 1 | Not yet recruiting | Eli Lilly and Company | 108 | 2026-11-01 | 2026-11-04 |
| Brain Dopamine Dynamics in Obesity Milkshake, NeuroEXPLORER, [11C]raclopride - Obesity | Phase 1 | Not yet recruiting | Yale University | 100 | 2026-11-01 | 2026-11-04 |
| A Study to Investigate the Effect of Injection Site and Ethnicity on KAI-4729 Pharmacokinetics in Non-Asian and Asian Participants Living With Obesity or Overweight KAI-4729 - Overweight or Obesity | Phase 1 | Not yet recruiting | Kailera | 60 | 2026-11-01 | 2026-11-09 |
| A Study to Learn How Different Amounts of the Study Medicine Called PF-08656795 Are Tolerated and Act in Adults With Overweight or Obesity Placebo, PF-08656795 - Overweight and/or Obesity | Phase 1 | Not yet recruiting | Pfizer | 150 | 2026-10-30 | 2026-10-15 |
| Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Hepatic Impairment and Normal Hepatic Function DA-302168S - Obesity, Overweight, T2DM (Type 2 Diabetes Mellitus) | Phase 1 | Not yet recruiting | Chendu DIAO Pharmaceutical Group CO., LTD. | 32 | 2026-10-22 | 2026-10-15 |
| A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or Obesity Berobenatide - Overweight and/or Obesity, Healthy Participants | Phase 1 | Recruiting | Pfizer | 144 | 2026-10-16 | 2026-11-06 |
| Study of UBT37034 Injection UBT37034, Placebo - Overweight , Obesity | Phase 1 | Recruiting | The United Bio-Technology (Hengqin) Co., Ltd. | 40 | 2026-10-15 | 2026-11-05 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC36 Tablets for Oral Use in Adult Participants With Obesity or Overweight ASC36 tablets, for oral use, ASC36 placebo tablets - Chronic Weight Management | Phase 1 | Recruiting | Ascletis Pharma (China) Co., Limited | 86 | 2026-10-13 | 2026-10-23 |
| A Study to Learn About the Study Medicine Called PF-08653944 in Otherwise Healthy Chinese Adults With Overweight or Obesity PF-08653944 - Overweight, Obesity | Phase 1 | Active not recruiting | Pfizer | 11 | 2026-10-13 | 2026-11-06 |
| Comparing the Extent to Which Two Maridebart Cafraglutide Drug Products Are Made Available in the Body After a Single Subcutaneous Dose Maridebart Cafraglutide - Overweight, Obesity | Phase 1 | Not yet recruiting | Amgen | 340 | 2026-10-12 | 2026-09-22 |
Showing 20 of 796. Sign in to see all of them.
Obesity (728) · Diabetes Mellitus, Type 2 (87) · Insulin Resistance (38) · Weight Loss (37) · Diabetes Mellitus (36) · Nutrition Disorders (27) · Metabolic Syndrome (23) · Non-alcoholic Fatty Liver Disease (23) · Hypertension (19) · Motor Activity (19) · Obesity, Morbid (16) · Body Weight (14) · Metabolic Diseases (13) · Cardiovascular Diseases (12)
Nutritional and Metabolic Diseases (795) · Overnutrition (793) · Pathological Conditions, Signs and Symptoms (789) · Signs and Symptoms (784) · Body Weight (771) · Nutrition Disorders (769) · Glucose Metabolism Disorders (158) · Metabolic Diseases (157) · Endocrine System Diseases (125) · Diabetes Mellitus (86) · Hyperinsulinism (48) · Body Weight Changes (42) · Behavior (38) · Digestive System Diseases (34)
semaglutide (35) · Acetaminophen (18) · Tirzepatide (17) · Sodium Chloride (16) · Metformin (15) · Liraglutide (12) · Rosuvastatin Calcium (12) · BI 456906 (10) · cagrilintide (10) · Exercise (9) · Warfarin (9) · Atorvastatin (8) · Digoxin (8) · Glucagon (8) · Glucose (7)
Novo Nordisk A/S (86) · Eli Lilly and Company (40) · Pfizer (31) · AstraZeneca (24) · Amgen (17) · Boehringer Ingelheim (16) · Vanderbilt University Medical Center (14) · Mayo Clinic (12) · GlaxoSmithKline (10) · Columbia University (9) · BrightGene Bio-Medical Technology Co., Ltd. (8) · Shanghai Minwei Biotechnology Co., Ltd (8) · Stanford University (8) · University of Pittsburgh (8) · Yale University (8)
United States (417) · China (102) · Germany (46) · Australia (37) · United Kingdom (31) · Canada (27) · Singapore (12) · South Korea (11) · France (10) · Japan (10) · Netherlands (10) · Denmark (9) · Brazil (8) · Sweden (7) · Belgium (6)
Joshua R Cook, MD, PhD (7) · Jack A Yanovski, M.D. (5) · John M Jakicic, Ph.D. (4)
PMID 12150647, PMID 36524539, PMID 36690550, PMID 41747885, PMID 10560680, PMID 11245554, PMID 11433905, PMID 12679447, PMID 12841897, PMID 15598683, PMID 15671108, PMID 15681386, PMID 16818482, PMID 16864756, PMID 17065354, PMID 17116758, PMID 18310192, PMID 18316660, PMID 18400730, PMID 18491071, PMID 18635428, PMID 18825363, PMID 18957534, PMID 19142567, PMID 19433800, PMID 19461456, PMID 19475464, PMID 19487105, PMID 19698154, PMID 19796996, PMID 19816674, PMID 19934630, PMID 20194883, PMID 20214807, PMID 20457158, PMID 20528109, PMID 20551965, PMID 20725058, PMID 20810979, PMID 20847735, PMID 20881066, PMID 21169160, PMID 21190985, PMID 21229331, PMID 21233083, PMID 21464376, PMID 21779093, PMID 21820871, PMID 21834938, PMID 21865361
2025 (13), 2023 (7), 2019 (5), 2014 (4), 2018 (3), K23DK140614 (3), P30DK063608 (3), 2009 (2), K12DK133995 (2), K23HL103976 (2), K24DK059492 (2), R01DK091748 (2), 1OT2CA297680-01 (1), 2008 (1), 2017 (1)